MAP kinase-targeting diet for dogs with cancer
This technology is a precisely formulated pet food or supplement designed to reduce the activity of a specific cellular signaling pathway (MAP kinase) that is linked to cancer growth and abnormal tissue proliferation in animals. The formula specifies exact ratios and concentrations of omega-3 and omega-6 fatty acids, combined with a high-protein, low-carbohydrate nutritional profile. The idea is that feeding animals this composition can have a therapeutic effect, potentially slowing or managing cancer or tissue overgrowth through diet alone. It covers food, supplements, treats, and even toys intended for animal consumption.
What you could build
A prescription or veterinarian-recommended pet food line (primarily for dogs) marketed as a cancer-supportive diet, sold through veterinary clinics and specialty pet health retailers to pet owners managing a diagnosed animal cancer patient.
Who in Virginia should care
Veterinary schools, pet food manufacturers, or animal health companies operating in Virginia would be the most natural fit, along with biotech firms focused on companion animal therapeutics.
Readiness: Concept
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Kathy L. Gross, Inke Paetau-Robinson, Korinn E. Saker
- Granted
- March 19, 2013
- Status
- Granted patent
- Patent number
- 8399411
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.